Association between Genetic Polymorphism of The lncRNA MIAT rs1894720 with Ischemic Stroke Risk and lncRNA MIAT Expression Levels in The Blood after An Ischemic Stroke: A Case-Control Study

Document Type : Original Article

Authors

1 Department of Biology, Zarghan Branch, Islamic Azad University, Zarghan, Iran

2 Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

3 Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Objective: Genetic aspects can play an essential role in the occurrence and development of ischemic stroke (IS).
Rs1894720 polymorphism is one of the eight single nucleotide polymorphisms (SNPs) in the long non-coding RNA
(lncRNA) myocardial infarction-associated transcript (MIAT) locus. The aim of study is the lncRNA MIAT rs1894720
polymorphism decreases IS risk by reducing lncRNA MIAT expression.
Materials and Methods: In this case-control study, we studied 232 Iranian patients and 232 controls. The blood samples
were collected from patients admitted at different times after stroke symptoms. We enrolled 80, 78, and 74 patients
who arrived at the hospital between 0-24, 24-48, and 48-72 hours after the first appearance of symptoms, respectively.
DNA genotyping was done by the tetra-primer ARMS-PCR method. Circulating MIAT levels were evaluated by real-time
polymerase chain reaction (PCR).
Results: The GT genotype of MIAT rs1894720 showed a significant association with the risk of IS (OR=3.53, 95%
CI=2.13-5.84, P<0.001). MIAT expression was higher relative to the control within the first hours after IS. The MIAT
levels in IS patients with rs1894720 (GT) were significantly lower relative to patients who had the GG and TT genotypes.
Linear regression model indicated a significant correlation between MIAT expression with atherosclerotic risk factors
and types of stroke in IS patients. Receiver operating characteristic (ROC) curve analysis showed that the level of
lncRNA MIAT after IS could be diagnostic with an area under the curve (AUC) of 0.82. The sensitivity and specificity
were 80.17 and 67.24%, respectively (P<0.001).
Conclusion: Our study demonstrated that the MIAT rs1894720 polymorphism (GT) might increase the risk of IS in the
Iranian population. MIAT expression was up-regulated in our IS patients. Hence, it could be a diagnostic biomarker for IS.

Keywords

Main Subjects


  1. Torres-Aguila NP, Carrera C, Muiño E, Cullell N, Cárcel-Márquez J, Gallego-Fabrega C, et al. Clinical variables and genetic risk factors associated with the acute outcome of ischemic stroke: a systematic review. J Stroke. 2019; 21(3): 276-289.
  2. Nikolic D, Jankovic M, Petrovic B, Novakovic I. Genetic aspects of inflammation and immune response in stroke. Int J Mol Sci. 2020; 21(19): 7409.
  3. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021; 22(2): 96-118.
  4. Bao MH, Szeto V, Yang BB, Zhu SZ, Sun HS, Feng ZP. Long non-coding RNAs in ischemic stroke. Cell Death Dis. 2018; 9(3): 281.
  5. Shen S, Jiang H, Bei Y, Xiao J, Li X. Long non-coding RNAs in cardiac remodeling. Cell Physiol Biochem. 2017; 41(5): 1830- 1837.
  6. Sun C, Huang L, Li Z, Leng K, Xu Y, Jiang X, et al. Long noncoding RNA MIAT in development and disease: a new player in an old game. J Biomed Sci. 2018; 25(1): 23.
  7. Zhu M, Li N, Luo P, Jing W, Wen X, Liang C, et al. Peripheral blood leukocyte expression of lncRNA MIAT and its diagnostic and prognostic value in ischemic stroke. J Stroke Cerebrovasc Dis. 2018; 27(2): 326-337.
  8. Qu X, Du Y, Shu Y, Gao M, Sun F, Luo S, et al. MIAT Is a Profibrotic long non-coding RNA governing cardiac fibrosis in postinfarct myocardium. Sci Rep. 2017; 7: 42657.
  9. Yan B, Yao J, Liu JY, Li XM, Wang XQ, Li YJ, et al. lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. Circ Res. 2015; 116(7): 1143-1156.
  10. Li Y, Zhang W, Ke H, Wang Y, Duan C, Zhu Q, et al. Rs1894720 polymorphism is associated with the risk of age-related cataract by regulating the proliferation of epithelial cells in the lens via the signalling pathway of MIAT/miR-26b/BCL2L2. Arch Med Sci. 2020; 18(1): 223-236.
  11. Ji TT, Qi YH, Li XY, Tang B, Wang YK, Zheng PX, et al. Loss of lncRNA MIAT ameliorates proliferation and fibrosis of diabetic nephropathy through reducing E2F3 expression. J Cell Mol Med. 2020; 24(22): 13314-13323.
  12. Gong J, Liu W, Zhang J, Miao X, Guo AY. lncRNASNP: a database of SNPs in lncRNAs and their potential functions in human and mouse. Nucleic Acids Res. 2015; 43(Database issue): D181-D186.
  13. Ma R, He X, Zhu X, Pang S, Yan B. Promoter polymorphisms in the lncRNA-MIAT gene associated with acute myocardial infarction in Chinese Han population: a case-control study. Biosci Rep. 2020; 40(2): BSR20191203.
  14. Rao SQ, Hu HL, Ye N, Shen Y, Xu Q. Genetic variants in long non-coding RNA MIAT contribute to risk of paranoid schizophrenia in a Chinese Han population. Schizophr Res. 2015; 166(1- 3): 125-130.
  15. Ghapanchi J, Mokhtari MJ, Zahed M, Ardekani ST, Fattahi MJ, Khademi B, et al. Genetic analysis of lncRNA H19 (rs217727) and MIAT (rs1894720) polymorphisms in patients with salivary gland tumors. Gene Reports. 2023; 30: 101724.
  16. Hao S, Wang L, Zhao K, Zhu X, Ye F. Rs1894720 polymorphism in MIAT increased susceptibility to age-related hearing loss by modulating the activation of miR-29b/SIRT1/PGC-1α signaling. J Cell Biochem. 2019; 120(4): 4975-4986.
  17. Zhu W, Tian L, Yue X, Liu J, Fu Y, Yan Y. LncRNA expression profiling of ischemic stroke during the transition from the acute to subacute stage. Front Neurol. 2019; 10: 36.
  18. Guo X, Wang Y, Zheng D, Cheng X, Sun Y. LncRNA-MIAT promotes neural cell autophagy and apoptosis in ischemic stroke by up-regulating REDD1. Brain Res. 2021; 1763: 147436.
  19. Qi Y, Wu H, Mai C, Lin H, Shen J, Zhang X, et al. LncRNA-MIATmediated miR-214-3p silencing is responsible for IL-17 production and cardiac fibrosis in diabetic cardiomyopathy. Front Cell Dev Biol. 2020; 8: 243.
  20. Sedova P, Brown RD, Zvolsky M, Belaskova S, Volna M, Baluchova J, et al. Incidence of stroke and ischemic stroke subtypes: a community-based study in brno, czech republic. Cerebrovasc Dis. 2021; 50(1): 54-61.
  21. Lin CH, Wei JN, Fan KC, Fang CT, Wu WC, Yang CY, et al. Different cutoffs of hypertension, risk of incident diabetes and progression of insulin resistance: a prospective cohort study. J Formos Med Assoc. 2022; 121(1 Pt 1): 193-201.
  22. Zhuo Y, Qu Y, Wu J, Huang X, Yuan W, Lee J, et al. Estimation of stroke severity with National Institutes of Health Stroke Scale grading and retinal features: a cross-sectional study. Medicine (Baltimore). 2021; 100(31): e26846.
  23. Liu X, Zhou M, Zhao J, Gao Y, Wang Y, Zhou J, et al. Functional independence and disability evaluation in stroke patients: optimal cutoff scores for a pictorial-based longshi scale, barthel index, and modified rankin scale. Front Neurol. 2022; 13: 710852.
  24. Harris S, Sungkar S, Rasyid A, Kurniawan M, Mesiano T, Hidayat R. TOAST subtypes of ischemic stroke and its risk factors: a hospital-based study at Cipto Mangunkusumo Hospital, Indonesia. Stroke Res Treat. 2018; 2018: 9589831
  25. Zhang S, Dang Y, Zhang Q, Qin Q, Lei C, Chen H, et al. Tetraprimer amplification refractory mutation system PCR (T-ARMSPCR) rapidly identified a critical missense mutation (P236T) of bovine ACADVL gene affecting growth traits. Gene. 2015; 559(2): 184-188.
  26. Rezaei M, Mokhtari MJ, Bayat M, Safari A, Dianatpuor M, Tabrizi R, et al. Long non-coding RNA H19 expression and functional polymorphism rs217727 are linked to increased ischemic stroke risk. BMC Neurol. 2021; 21(1): 54.
  27. Sun G, Li Y, Ji Z. Up-regulation of MIAT aggravates the atherosclerotic damage in atherosclerosis mice through the activation of PI3K/Akt signaling pathway. Drug Deliv. 2019; 26(1): 641- 649.
  28. Arslan S, Berkan Ö, Lalem T, Özbilüm N, Göksel S, Korkmaz Ö, et al. Long non-coding RNAs in the atherosclerotic plaque. Atherosclerosis. 2017; 266: 176-181.
  29. Ye ZM, Yang S, Xia YP, Hu RT, Chen S, Li BW, et al. LncRNA MIAT sponges miR-149-5p to inhibit efferocytosis in advanced atherosclerosis through CD47 upregulation. Cell Death Dis. 2019; 10(2): 138.
  30. Duan H, Zhang Q, Liu J, Li R, Wang D, Peng W, Wu C. Suppression of apoptosis in vascular endothelial cell, the promising way for natural medicines to treat atherosclerosis. Pharmacol Res. 2021; 168: 105599
  31. Vausort M, Wagner DR, Devaux Y. Long noncoding RNAs in patients with acute myocardial infarction. Circ Res. 2014; 115(7): 668-677.
  32. Keihani S, Kluever V, Fornasiero EF. Brain long noncoding RNAs: multitask regulators of neuronal differentiation and function. Molecules. 2021; 26(13): 3951.
  33. Karlsson WK, Sørensen CG, Kruuse C. l-arginine and l-NMMA for assessing cerebral endothelial dysfunction in ischaemic cerebrovascular disease: a systematic review. Clin Exp Pharmacol Physiol. 2017; 44(1): 13-20.
  34. Jiang Q, Shan K, Qun-Wang X, Zhou RM, Yang H, Liu C, et al. Long non-coding RNA-MIAT promotes neurovascular remodeling in the eye and brain. Oncotarget. 2016; 7(31): 49688-49698.
  35. Dykstra-Aiello C, Jickling GC, Ander BP, Shroff N, Zhan X, Liu D, et al. Altered expression of long noncoding rnas in blood after ischemic stroke and proximity to putative stroke risk loci. Stroke. 2016; 47(12): 2896-2903.
  36. Azat M, Huojiahemaiti X, Gao R, Peng P. Long noncoding RNA MIAT: a potential role in the diagnosis and mediation of acute myocardial infarction. Mol Med Rep. 2019; 20(6): 5216-5222.
  37. Pardini B, Sabo AA, Birolo G, Calin GA. Noncoding RNAs in extracellular fluids as cancer biomarkers: the new frontier of liquid biopsies. Cancers (Basel). 2019; 11(8): 1170. 38.
  38. Ghafouri-Fard S, Shirvani-Farsani Z, Hussen BM, Taheri M, Arefian N. Emerging impact of non-coding rnas in the pathology of stroke. Front Aging Neurosci. 2021; 13: 780489.
  39. Tellez-Gabriel M, Heymann D. Exosomal lncRNAs: the newest promising liquid biopsy. Cancer Drug Resist. 2019; 2(4): 1002- 1017.
  40. Shi T, Gao G, Cao Y. Long noncoding RNAs as novel biomarkers have a promising future in cancer diagnostics. Dis Markers. 2016; 2016: 9085195.